180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to ShareholdersGlobeNewsWire • 12/29/22
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 12/23/22
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 12/20/22
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance PlanGlobeNewsWire • 12/16/22
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's ContractureGlobeNewsWire • 11/30/22
180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 – December 1, 2022GlobeNewsWire • 11/21/22
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's DiseaseGlobeNewsWire • 11/15/22
180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen ShoulderGlobeNewsWire • 08/22/22
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program WiGlobeNewsWire • 07/27/22
180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's DiseaseGlobeNewsWire • 06/14/22
180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren's DiseaseGlobeNewsWire • 05/31/22
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet RheumatologyGlobeNewsWire • 04/29/22
180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022GlobeNewsWire • 12/28/21
180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver DiseasesGlobeNewsWire • 12/15/21
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's Successful Dupuytren's Phase 2b Clinical Trial ResultsGlobeNewsWire • 12/06/21
180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical TrialGlobeNewsWire • 12/01/21